Recent News

• 11.07.2025 - Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
• 10.19.2025 - Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
• 09.18.2025 - Replimune Provides Update Following Type A Meeting with FDA
• 09.18.2025 - Replimune Provides Update Following Type A Meeting with FDA
• 09.18.2025 - Replimune Provides Update Following Type A Meeting with FDA
• 09.02.2025 - Replimune Announces Type A Meeting Scheduled with FDA
• 09.02.2025 - Replimune Announces Type A Meeting Scheduled with FDA
• 09.02.2025 - Replimune Announces Type A Meeting Scheduled with FDA
• 08.07.2025 - Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Recent Filings

• 11.06.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - S-3/A Registration statement under Securities Act of 1933
• 10.20.2025 - EX-99.1 EX-99.1
• 10.20.2025 - 8-K Current report
• 09.18.2025 - 8-K Current report
• 09.18.2025 - EX-99.1 EX-99.1
• 09.04.2025 - EX-99.1 EX-99.1
• 09.04.2025 - 8-K Current report